- On **September 26, 2025**, SAB Biotherapeutics, Inc. stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, increasing the maximum number of shares available to plan participants by **24,180,000 shares** to an aggregate of **31,932,466 shares**.  **[1833214_0001193125-25-220721_sabs-20250926.htm:0]** **[1833214_0001193125-25-220721_sabs-20250926.htm:1]** 
- The amendment also significantly increased the maximum number of additional shares available for issuance through the annual evergreen increase from **10,000,000 shares** to **73,750,000 shares**.  **[1833214_0001193125-25-220721_sabs-20250926.htm:0]** **[1833214_0001193125-25-220721_sabs-20250926.htm:1]** 
- Stockholders further approved the potential issuance of Series B Convertible Preferred Stock in excess of **19.99%** of the Company's outstanding Common Stock.  **[1833214_0001193125-25-220721_sabs-20250926.htm:1]** 
- The Special Meeting, held on **September 26, 2025**, had **6,053,045 shares** present, constituting a **54.5%** quorum of the **11,099,061 shares** entitled to vote.  **[1833214_0001193125-25-220721_sabs-20250926.htm:0]**

SAB Biotherapeutics (SABS)